Nicotinamide drives T cell activation in the mammary tumor microenvironment. uri icon

Overview

abstract

  • Nicotinamide (NAM, a variant of vitamin B3) has recently been shown to accelerate the activation of human CD4+ and CD8+ T cells exposed to repeated CD3/CD28 agonism in vitro. Here, we demonstrate that T cells infiltrating mouse mammary carcinomas that are therapeutically controlled by NAM also express multiple markers of late-stage activation. Taken together, these findings lend additional support to the notion that the antineoplastic effects of NAM involve at least some degree of restored cancer immunosurveillance.

publication date

  • June 3, 2022

Research

keywords

  • Niacinamide
  • Tumor Microenvironment

Identity

PubMed Central ID

  • PMC9164530

Scopus Document Identifier

  • 85131202444

Digital Object Identifier (DOI)

  • 10.1038/s41571-019-0297-y

PubMed ID

  • 35659314

Additional Document Info

volume

  • 20

issue

  • 1